Results 241 to 250 of about 160,542 (279)

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions. [PDF]

Cancer Med
Li S, Wang J, Liu Y, Cai W, Zhang W, Li S, Zhang Y.   +6 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trial. [PDF]

ESMO Gastrointest Oncol
Okemoto D, Kotani D, Nakamura M, Sato K, Kubo Y, Kadota T, Mishima S, Sakashita S, Hashimoto T, Bando H, Wakabayashi M, Rabinowitz M, Liu MC, Jurdi A, Yamaguchi T, Nishikawa H, Shitara K, Yano T, Kojima T, Fujita T.   +19 more
europepmc   +1 more source

The China Paradox in LEAP-012 Trial. [PDF]

Liver Cancer
Kudo M.
europepmc   +1 more source

Immune Checkpoint Inhibitor-Induced Sarcoidosis-Like Reaction Mimicking Pulmonary Metastasis: A Case Report. [PDF]

Cureus
Sawada M, Kurose Y, Ochi Y, Kanno K, Andou M.   +4 more
europepmc   +1 more source

From prevention to progression: can belzutifan-based strategies deliver across the RCC disease continuum? [PDF]

Oncologist
Beckermann K.
europepmc   +1 more source

Chronic rhinosinusitis during immune checkpoint inhibition in melanoma patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Sinja Sistani, Mareike Alter, Ralf Gutzmer   +3 more
wiley   +1 more source

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer. [PDF]

Clin Cancer Res
Rubinstein MM, Ge JY, Zhou Q, Iasonos A, Weigelt B, Selenica P, Muldoon DM, Bandlamudi C, Kaczynski C, Paroder V, Higgins K, Shah P, Weissblum S, Lyn A, Liu YL, Bose S, Cohen SM, Green AK, Grisham RN, Kyi C, O'Cearbhaill RE, Tew WP, Berger MF, Aghajanian C, Makker V.   +24 more
europepmc   +1 more source

Response to a combination therapy of cemiplimab and cetuximab in cutaneous squamous cell carcinoma – a case report

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Katja Schabet, Louisa Schielein, Alexander Enk, Jessica C. Hassel   +3 more
wiley   +1 more source